The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ATRC | +29.6% | -1.5% | -0.3% | +166% |
| S&P | +14.5% | +93.32% | +14.09% | +446% |
AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded in 1994 and is headquartered in Mason, OH.
Find out which of these companies did a great job raising money.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $136.14M | 17.1% |
| Gross Profit | $100.72M | 17.0% |
| Gross Margin | 73.98% | -0.1% |
| Market Cap | $1.62B | 47.3% |
| Market Cap / Employee | $1.25M | 0.0% |
| Employees | 1.3K | 8.3% |
| Net Income | -$6.19M | 22.7% |
| EBITDA | $3.98M | 250.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $117.80M | 11.1% |
| Accounts Receivable | $66.00M | 18.8% |
| Inventory | 76.3 | 3.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $74.34M | 2.2% |
| Short Term Debt | $2.91M | 14.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -6.03% | 0.7% |
| Return On Invested Capital | -4.79% | 0.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $18.96M | 223.7% |
| Operating Free Cash Flow | $21.62M | 162.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.94 | 3.20 | 3.42 | 3.57 | 47.78% |
| Price to Sales | 2.95 | 3.10 | 3.18 | 3.13 | 25.91% |
| Price to Tangible Book Value | 7.95 | 8.67 | 9.29 | 9.80 | 41.82% |
| Price to Free Cash Flow TTM | 137.50 | 64.57 | - | ||
| Enterprise Value to EBITDA | -511.76 | 605.28 | -1731.52 | 382.83 | -198.22% |
| Free Cash Flow Yield | 0.7% | 1.5% | - | ||
| Return on Equity | -8.4% | -9.6% | -8.4% | -7.8% | -9.58% |
| Total Debt | $77.13M | $76.53M | $77.41M | $77.25M | 2.57% |
ATRC earnings call for the period ending September 30, 2021.
ATRC earnings call for the period ending June 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
